Viewing Study NCT04540705


Ignite Creation Date: 2025-12-25 @ 3:37 AM
Ignite Modification Date: 2025-12-26 @ 2:21 AM
Study NCT ID: NCT04540705
Status: COMPLETED
Last Update Posted: 2024-02-28
First Post: 2020-09-03
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread
Sponsor: Bristol-Myers Squibb
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module